News

How Regeneron Aims to Stay on Message With VR/AR APP

By Jackie Wengrod | March 29, 2017

Virtual reality has been used to train surgeons, to evaluate balance control and associated fall risk in glaucoma patients, and, more recently, to create simulations…

Allergan Makes a Play in Gene Editing

By Jackie Wengrod | March 22, 2017

With its licensing agreement to develop genome-editing programs with Editas Medicine to treat retinal diseases, Allergan has made a move to partner with one of…

Clearside Goes All in for CLS-TA

By Jackie Wengrod | March 15, 2017

Late last year, when developers of agents that combined anti-platelet derived growth factor with an anti-vascular endothelial growth factor (anti-PDGF/anti-VEGF) to treat wet age-related macular…

How J&J’s Janssen Targets Disruptive Treatments in Ophthalmology

By Jackie Wengrod | March 8, 2017

A few weeks before Johnson & Johnson completed its acquisition of Abbott Medical Optics to bring under its J&J Vision umbrella, another J&J unit, Janssen…

Deal between Minnesota Eye Consultants and Waud Capital Signals Change Coming to Ophthalmology

By Jackie Wengrod | March 3, 2017

Two years ago, the principals at Minnesota Eye Consultants recognized the time had come to find a way to expand the practice. But doing so…

Eye on Five – February Edition 2017

By Jackie Wengrod | March 2, 2017

Envisia Candidate Achieves Endpoint for IOP Lowering Envisia Therapeutics released Phase II results showing that its ENV515 candidate (travoprost XR) achieved clinically meaningful intraocular pressure…

OIS Index Rebounds – Delivers Positive Performance in February

By Jackie Wengrod | March 2, 2017

In October, we launched the OIS Index, a composite of ophthalmic growth stocks, to track the investment performance of our sector. Our goal is to…

What’s Behind the Heat-up in Glaucoma Innovation

By Jackie Wengrod | February 22, 2017

Kicking off the sixth annual Glaucoma 360-New Horizons Forum held recently in San Francisco, co-founder and co-chair Adrienne Graves boldly proclaimed, “Glaucoma is hot.” However,…

Roche/Genentech’s Second Move to Protect Lucentis Franchise

By Jackie Wengrod | February 15, 2017

With its patents on Lucentis set to expire in a few years and clinical trials of at least three Lucentis biosimilars underway, Roche’s recent acquisition…

Is DR Just the Start for Google Brain?

By Jackie Wengrod | February 9, 2017

A team of investigators recently reported online in the Journal of the American Medical Association1 that a Google algorithm allows computers to diagnose diabetic retinopathy…